This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Monkeypox Treatment Market

Market Insights on Monkeypox Treatment covering sales outlook, demand forecast & up-to-date key trends

Monkeypox Treatment Market by Treatment Type, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033

Monkeypox Treatment Market Snapshot (2023 to 2033)

The global monkeypox treatment market is expected to reach a valuation of US$ 93.84 million in 2023 and is projected to grow to US$ 249 million by 2033, registering a CAGR of 10.25% during the forecast period. The demand for effective treatment, vaccination, and other rare disease therapeutics are anticipated to propel growth of the global monkeypox therapeutics market during the forecast period.

There is presently no specific treatment or defined pharmaceutical for the disease, but symptomatic treatment is possible, and a rise in demand for pain and itch relief caused by boils and rashes are positively impacting growth of monkeypox treatment market. Moreover, surge in the products approvals is also projected to fuel monkeypox treatment market during the forecast period.

Likewise, according to the United states Food and Drug Administration, on 9 August 2022, Bavarian Nordic, a completely integrated vaccine company concentrated on the development, manufacturing and commercialization of life-saving vaccines, declared that its Jynneos vaccine received the approval from United states food and drugs administration as an emergency drug for treatment of growing monkeypox disease. This will help in expansion of market in the forecast period.

Report Attribute

Details

Expected Market Value (2023)

US$ 93.84 million

Anticipated Forecast Value (2033)

US$ 249 million

Projected Growth Rate (2023 to 2033)

CAGR 10.25%

Customize this Report

Let us know your requirement to get
100% FREE customization

2018 to 2022 Monkeypox Treatment Management Demand Analysis vs. Forecast 2023 to 2033

The market for Monkeypox treatment was worth US$ 64 million in 2018, while growing at a CAGR of 7.95 % during the historical period. Mounting demand of monkeypox treatment and increasing research for specific treatment for monkeypox led to vast opportunities which will aid in market expansion. Governments around the world are pro-actively investing in the research and development for the development of effective drug and vaccines to control the growing number of monkeypox cases.

On the other hand, various governments have started promoting genetic engineering for development of vaccines and also begun campaigns for spreading awareness about the potential disease cause and prevention. In addition, rise in healthcare expenditure day by day for advance in treatment of monkeypox disease will witness profitable growth prospects during the forecast period that will benefit the market in long-term.

For instance, In North America and various European countries, approval of two vaccines and antiviral drug for treatment of monkeypox, previously used for smallpox treatment and eradication will lead to market expansion in the projected period. The live attenuated vaccine, Imvanex (in Europe) Jynneos (in the USA) is developed by Bavarian Nordic. Likewise, smallpox shot ACAM2000 was developed by EMERGENT (Emergent BioSolutions). Considering the above-mentioned factors, product approvals and developments, the monkeypox treatment market is projected to reach US$ 249 million by 2033, with a CAGR of 10.25%.

Which are Some Prominent Drivers of the Monkeypox Treatment Market?

Surging demand for timely vaccines and potential disease treatments is expected to drive growth of monkeypox treatment market during the forecast period. Active investments in the research and development of effective vaccines and drugs to manage disease spread and treat affected patients is driving growth of this market. Additionally, the government is taking steps to facilitate drug development by utilizing genetic engineering tools in order to provide vaccination in the event that the virus evolves and impacts massive portion of the populace.

On the other hand, genomic sequencing for the virus would unravel the specific infection-causing sequences, which could help in the early diagnosis of viral infection and the development of effective vaccines for the population at risk of infection in the forthcoming period. Also, increasing healthcare expenditures by the population is fuelling investments for the development of new vaccines, which will drive global monkeypox treatment market during the projected period. Currently, tecovirimat is the treatment of choice for people in treating monkeypox. This is expected to propel growth during the forecast period.

Likewise, EMA’s human medicines committee recommended an extension of the indication of smallpox vaccine IMVANEX to protect people from monkeypox infection. IMVANEX was approved in 2013 but it has been considered a crucial vaccine because of the similarities between smallpox and monkeypox. Furthermore, increasing Research and development activities and use of smallpox vaccine as an off-label product for vaccination against monkeypox are anticipated to propel market in the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Projected to be Faced by the Market?

Side-effects related to drug use to restrain market expansion

The growing side effects related to the drugs used to treat monkeypox, is anticipated to restrict growth of the market. Dearth of awareness and knowledge of the disease about the supportive treatment and slow approval rate of specific therapeutic treatment for monkeypox are the major factor expected to restrain growth of this market.

Region-Wise Insights

What is the growth outlook in North America?

North America expected to dominate market with maximum share

North America dominated the market with a revenue share of 40.5% in 2022. It is projected to possess around 48% market share by end of the forecast period while growing at a CAGR of 9.1%. Growth is attributed to presence of many dominating players, coupled with numerous strategic initiatives undertaken by them. Also, the rise in disease prevalence and growing awareness among people regarding vaccination are estimated to propel growth of regional market. Additionally, favorable support from the government and higher research and development investments are expected to provide lucrative opportunities for market growth of monkeypox treatment in this region.

In addition, on 4 august 2022, the United States department of health and human services, announced monkeypox outbreak as a public health emergency. Due to this, there is a surging demand for vaccines and better treatment for monkeypox. Also, rising prevalence of monkeypox disease and growing demand for vaccines and new treatment for monkeypox is projected to fuel growth of the monkeypox treatment market in this region.

Similarly, the United states government included the ACAM2000 drug in its strategic stockpile for the treatment of monkeypox. However, it is not commercially available yet. Presently, Siga Technologies’ Tecovirimat (TPOXX) and Chimerix’s brincidofovir (TEMBEXA) are only two FDA-approved drugs for smallpox that are generally recommended for the treatment of certain patients with monkeypox. These approvals will help in expansion of market in this region during the forecast period.

What is the growth prospect in Asia-Pacific?

Asia Pacific market expected to reflect fastest CAGR

Asia Pacific is projected to witness the fastest growth of 11% during the forecast period. The growing number of monkeypox infections and increasing research and development activities for developing prevention and therapeutic options are some of the primary factors fuelling market growth.

Rising prevalence of infection in Asia Pacific countries such as Singapore, Australia, and India are anticipated to propel market growth.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category wise Insights

By route of administration, which segment will possess significant share?

Oral segment to dominate market with maximum share

In 2022, the oral segment held the largest market share of 65.0% and it is estimated to possess more than 70% share by end of the forecast period. Surging demand for oral route therapeutics, ease of administration, and cost-effectiveness of oral products are some factors contributing to the segment expansion.

Likewise, most common drugs such as tecovirimat and brincidofovir are administered orally which are expected to boost growth of this segment during the forecast period.

By treatment type, which segment will possess market dominance?

Tecovirimat driving growth with maximum share

This segment is estimated to account for 61% market share in monkeypox treatment market by end of 2033. This drug is expected to grow with a CAGR of 11.2% during the forecast period. Growth is attributed to the accepted safety profile offered by Tecovirimat during the clinical trials and for the treatment of monkey pox in severe cases.

This drug is also accepted as first line of therapeutic treatment recommended by United states food and drug administration (FDA). It is also approved in European countries as well. The validation provided by these bodies and promising results from clinical trials are driving growth of this segment. Moreover, ‘Tecovirimat’ is proved to be only effective drug against human monkeypox virus in vitro at nanomolar concentrations. Thus, presenting opportunities for market expansion of this segment.

Start-ups in Monkeypox Treatment Market

Start-ups help in understanding the outlook of any market. Start-ups also have the potential to generate higher returns which directly benefits in expansion of any market. This is because these are typically more efficient at converting inputs into outputs. These are more flexible and adaptable, able to shift quickly in response to changing market conditions. Some of the start-ups that will aid in expansion of monkeypox treatment market are:

  • Chimirax is a Durham, United Kingdom based start-up, founded in 2002. It is the developer of antiviral oral therapeutics. Its product pipeline involves Brincidofovir for smallpox, ONC201 for mutant glioma, DSTAT for acute myeloid leukemia, and ONC206 for solid tumors. It enhances quality of life for patients in multiple settings, including transplant, oncology, acute care, and global health. It was granted total funding of USD 95.2 million from Morningside Ventures, Pappas Ventures, and 6 more.
  • Emergex is a United Kingdom-based start-up, founded in 2016. It is developing T-cell vaccines for treating viral and bacterial infections like monkeypox. The company also targets Zika, Ebola, pandemic flu, and antibiotic-resistant bacteria. The technology delivers immunogenic peptides which result in T-cell immune response. The dominant candidate of the company, EMX-001, which is a flavivirus vaccine. It is used to treat zika, dengue, and yellow fever. The candidate is in the preclinical stage. It received total funding of USD 30 million until February 2022.

Market Competition

The global Monkeypox treatment market is extremely competitive owing to presence of large number of players and innovative product offerings. Additionally, business expansion activities through partnerships and agreements are factors projected to further increase the competition. The major players in the market are: SIGA Technologies Inc., Chimerix, Inc, Bavarian Nordic, Sanofi SA, Emcure Pharmaceuticals, Jinan Jinda Pharmaceutical Chemistry Co., Ltd, Emergent Pharmaceuticals, Gilead Sciences, Inc., Hetero, Piramal Pharma Solutions

Some Recent Developments in the market are:

Key market players are concentrating on adoption of inorganic growth strategies such as acquisition, partnerships and collaboration in order to improve its product portfolio. This is anticipated to drive the global monkeypox treatment market.

  • In 2021, SIGA, a commercial-stage pharmaceutical company concentrated on the health security market, declared that it entered into a collaboration with Oxford University in the UK to provide ‘tecovirimat’ to treat individuals suffered from monkeypox in the Central African Republic (CAR).
  • In July 2022, Bavarian Nordic A/S declared that the company received an additional order for 2.5 million doses of JYNNEOS from the USA BARDA.
  • In August 2022, the United states FDA authorised emergency use of JYNNEOS vaccine intradermal injectable for healthcare professionals over 18 years of age and older determined to be at higher risk of monkeypox infection.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 93.84 million

Market Value in 2033

US$ 249 million

Growth Rate

CAGR of 10.25% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2018 to 2022

Forecast Period

2023 to 2033

Quantitative Units

Revenue in USD million and CAGR from 2023 to 2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Treatment Type
  • Route of Administration
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Countries Profiled

  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Indonesia
  • China
  • Japan
  • Malaysia
  • Singapore
  • Thailand
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel

Key Companies Profiled

  • SIGA Technologies Inc.
  • Chimerix, Inc.
  • Bavarian Nordic
  • Sanofi SA
  • Emcure Pharmaceuticals
  • Jinan Jinda Pharmaceutical Chemistry Co., Ltd
  • Emergent Pharmaceuticals
  • Gilead Sciences, Inc.
  • Hetero
  • Piramal Pharma Solutions

Customization

Available Upon Request

Key Segments Profiled in the Monkeypox Treatment Industry Survey

By Treatment Type:

  • Prophylactic- Vaccines
  • Therapeutic
    • Tecovirimat
    • Brincidofovir
    • Cidofovir

By Route of Administration:

  • Oral
  • Injectable

By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

FMI projects the global Monkeypox treatment market to expand at a 10.25 % value CAGR by 2033.

The global Monkeypox treatment market is expected to garner a market value of US$ 249 million by 2033.

FMI has projected North America to be one of the most lucrative regions for Monkeypox treatment market.

Asia Pacific region is anticipated to grow fastest during the forecast period.

Table of Content

1. Executive Summary | Monkeypox Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033

        5.3.1. Prophylactic – Vaccines

        5.3.2. Therapeutic

            5.3.2.1. Tecovirimat

            5.3.2.2. Brincidofovir

            5.3.2.3. Cidofovir

    5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Injectable

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

        7.3.1. Retail Pharmacies

        7.3.2. Hospital Pharmacies

        7.3.3. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. The USA

            9.2.1.2. Canada

        9.2.2. By Treatment Type

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment Type

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Treatment Type

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment Type

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom (UK)

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Treatment Type

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment Type

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Treatment Type

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment Type

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of Middle East and Africa

        13.2.2. By Treatment Type

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment Type

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. USA

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Treatment Type

            14.1.2.2. By Route of Administration

            14.1.2.3. By Distribution Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Treatment Type

            14.2.2.2. By Route of Administration

            14.2.2.3. By Distribution Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Treatment Type

            14.3.2.2. By Route of Administration

            14.3.2.3. By Distribution Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Treatment Type

            14.4.2.2. By Route of Administration

            14.4.2.3. By Distribution Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Treatment Type

            14.5.2.2. By Route of Administration

            14.5.2.3. By Distribution Channel

    14.6. UK

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Treatment Type

            14.6.2.2. By Route of Administration

            14.6.2.3. By Distribution Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Treatment Type

            14.7.2.2. By Route of Administration

            14.7.2.3. By Distribution Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Treatment Type

            14.8.2.2. By Route of Administration

            14.8.2.3. By Distribution Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Treatment Type

            14.9.2.2. By Route of Administration

            14.9.2.3. By Distribution Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Treatment Type

            14.10.2.2. By Route of Administration

            14.10.2.3. By Distribution Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Treatment Type

            14.11.2.2. By Route of Administration

            14.11.2.3. By Distribution Channel

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Treatment Type

            14.12.2.2. By Route of Administration

            14.12.2.3. By Distribution Channel

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Treatment Type

            14.13.2.2. By Route of Administration

            14.13.2.3. By Distribution Channel

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Treatment Type

            14.14.2.2. By Route of Administration

            14.14.2.3. By Distribution Channel

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Treatment Type

            14.15.2.2. By Route of Administration

            14.15.2.3. By Distribution Channel

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Treatment Type

            14.16.2.2. By Route of Administration

            14.16.2.3. By Distribution Channel

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Treatment Type

            14.17.2.2. By Route of Administration

            14.17.2.3. By Distribution Channel

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Treatment Type

            14.18.2.2. By Route of Administration

            14.18.2.3. By Distribution Channel

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Treatment Type

            14.19.2.2. By Route of Administration

            14.19.2.3. By Distribution Channel

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Treatment Type

            14.20.2.2. By Route of Administration

            14.20.2.3. By Distribution Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Treatment Type

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. SIGA Technologies Inc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Chimerix, Inc.

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Bavarian Nordic

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Sanofi SA

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Emcure Pharmaceuticals

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Jinan Jinda Pharmaceutical Chemistry Co., Ltd.

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Emergent Pharmaceuticals

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Gilead Sciences, Inc.

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Hetero

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Piramal Pharma Solutions

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Asia Pacific Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 19: Asia Pacific Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 20: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Table 21: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 23: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033

Table 24: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 17: Global Market Attractiveness by Treatment Type, 2023 to 2033

Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033

Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 37: North America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 57: Latin America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033

Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 77: Europe Market Attractiveness by Treatment Type, 2023 to 2033

Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033

Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Asia Pacific Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 82: Asia Pacific Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 83: Asia Pacific Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 94: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 97: Asia Pacific Market Attractiveness by Treatment Type, 2023 to 2033

Figure 98: Asia Pacific Market Attractiveness by Route of Administration, 2023 to 2033

Figure 99: Asia Pacific Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 100: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 101: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 102: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Route of Administration, 2023 to 2033

Figure 103: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Distribution Channel , 2023 to 2033

Figure 104: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 109: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 110: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 111: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033

Figure 112: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033

Figure 113: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033

Figure 114: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033

Figure 115: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033

Figure 116: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033

Figure 117: MIDDLE EAST AND AFRICA Market Attractiveness by Treatment Type, 2023 to 2033

Figure 118: MIDDLE EAST AND AFRICA Market Attractiveness by Route of Administration, 2023 to 2033

Figure 119: MIDDLE EAST AND AFRICA Market Attractiveness by Distribution Channel , 2023 to 2033

Figure 120: MIDDLE EAST AND AFRICA Market Attractiveness by Country, 2023 to 2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Marburg Virus Disease Therapeutics Market

Published : January 2023

Healthcare

Zika Virus Testing Market

Published : May 2021

Healthcare

Viral Molecular Diagnostics Market

Published : January 1970

Healthcare

Virology Market

Published : March 2022

Google translate

Monkeypox Treatment Market